Sort
10,766 grants matching “checkpoint inhibitor”
In Vivo Regulation and Inhibition of Ribonucleotide Reductase
$317,561Mingxia Huang · University Of Colorado Denver · R01 · FY2010 · CA
Investigating the PD-L1:NLRP3 signaling axis as a tumor intrinsic mechanism of adaptive resistance to anti-PD-1 antibody immunotherapy
$317,373Brent Allen Hanks · Duke University · R37 · FY2020 · CA
Project 1: Hypoxia and metabolic dysregulation as a targetable barrier to immunotherapy in head and neck squamous cell carcinoma (HNSCC)
$317,052Greg M. Delgoffe · University Of Pittsburgh At Pittsburgh · P50 · FY2022 · CA
Mechanism(s) of Hepatocyte Transformation by the Hepatitis B Virus X Protein
$317,018Ourania M. Andrisani · Purdue University · R01 · FY2015 · DK
"Role of Amplified Protein Kinases in Head and Neck Squamous Cell Carcinoma Progression and Therapy Resistance."
$317,000Pedro Torres-Ayuso · Temple Univ Of The Commonwealth · R03 · FY2023 · DE
The replication checkpoint and genomic fidelity in skin
$316,960Paul Nghiem · University Of Washington · R01 · FY2007 · AR
Mechanism of ultraviolet radiation induced immune tolerance
$316,899Hui Xu · University Of Alabama At Birmingham · R01 · FY2021 · AR
Manipulation of Tumor Specific Immunity
$316,778Hans Schreiber · University Of Chicago · R01 · FY2024 · CA
Project 1: Hypoxia and metabolic dysregulation as a targetable barrier to immunotherapy in head and neck squamous cell carcinoma (HNSCC)
$316,751Greg M. Delgoffe · University Of Pittsburgh At Pittsburgh · P50 · FY2023 · CA
FEEDBACK CONTROL OF THE CELL CYCLE
$316,654Harvard University · R37 · FY2000 · GM
Mechanism-Based Use of Chk1 Inhibitors in Pancreas Cancer
$316,600Jonathan Maybaum · University Of Michigan At Ann Arbor · R01 · FY2011 · CA
Prostate cancer chemoprevention by penta-galloyl-glucose
$316,438Junxuan Lu · University Of Minnesota · R01 · FY2010 · CA
Prostate cancer chemoprevention by penta-galloyl-glucose
$316,438Junxuan Lu · University Of Minnesota · R01 · FY2009 · CA
Project 4: Combined use of immunotherapy and targeted treatments for triple negative breast cancer
$316,411Kornelia Polyak · Dana-Farber Cancer Inst · P50 · FY2020 · CA
Checkpoint inhibitor treatment for EBV+ lymphoma among HIV+ individuals
$316,286Mark Roschewski · Division Of Basic Sciences - Nci · ZIA · FY2025 · CA
Biomaterials-based Germinal Center Niches for Understanding the B Cell Maturation and B cell receptor signaling
$316,069Ankur Singh · Georgia Institute Of Technology · R01 · FY2020 · AI
Combining targeted radionuclide therapy with a localized in situ vaccine to overcome immune suppression in the tumor microenvironment and augment T cell responses
$316,027Paul M Sondel · University Of Wisconsin-Madison · P01 · FY2022 · CA
Novel focused ultrasound enhanced calreticulin-nanoparticle for immune primed melanoma immunotherapy
$315,862Ashish Ranjan · Oklahoma State University Stillwater · R37 · FY2020 · CA
Immune exhaustion in perinatal HIV infection
$315,859Alka Khaitan · Indiana University Indianapolis · R21 · FY2020 · HD
Poisoning of PARP and Topoisomerase I to Treat Ovarian Cancer
$315,836Scott H Kaufmann · Mayo Clinic Rochester · P50 · FY2009 · CA
Development of Molecular Microbubble Probes and Ultrasound-Guidance in Immunotherapeutic Strategies
$315,823Ahmed El Kaffas · Stanford University · R21 · FY2020 · EB
Project 4: Immunovirotherapy
$315,793Richard G Vile · Mayo Clinic Rochester · P50 · FY2020 · CA
Project 3: Mechanisms of immunotherapy action
$315,724Marcia Haigis · Harvard Medical School · U54 · FY2020 · CA
Oncolytic Adenoviruses for Glioma Therapy
$315,660Frederick F Lang · University Of Tx Md Anderson Can Ctr · P50 · FY2019 · CA
Core 1: Biospecimen and Data Management Core
$315,569John B Sunwoo · Stanford University · U54 · FY2020 · CA